Negative Pressure Diuresis, Preliminary Results of a First In Human **Treatment of Cardiorenal Syndrome**

Alex M Parker, MD¹, Vincent G Bird, MD¹, Amir Kazory, MD¹, Janette N Bostick¹, Brittany Y McMichael², Michael B Williams, MD², Kurt A McCammon, MD², David A Baran, MD² 1. University of Florida, Gainesville, FL; 2. Eastern Virginia Medical School Sentara Hospital Norfolk, VA

Figure 2.


(24 hr)



INTRODUCTION

- Cardiorenal syndrome in the setting of acute decompensated heart failure is a significant and common complication of chronic heart failure.
- The mainstay of treatment is intravascular volume removal by diuresis and in recalcitrant cases ultrafiltration.
- We present the initial experience with a novel device (the JuxtaFlow[®] System) that utilizes negative pressure in the renal pelvis to promote diuresis.
- We refer to this therapy as renal Negative Pressure Diuresis (rNPD).

JUXTAFLOW[®] SYSTEM



400

350

300

250

200

150

100

50

Control

(24 hr)

HYPOTHESIS

 Placement of a novel renal negative pressure device leads to increased diuresis to treat acute decompensated heart failure with cardiorenal syndrome.



RESULTS

- The current study cohort consists of 3 patients meeting inclusion and exclusion criteria who underwent rNPD.
- Average urine output at baseline was 2.4 L per day which increased during the treatment period to 4.4 L per day. Increased urine output continued to be observed in the observational period with average urine output of 3.1 L per day (Figures 1 and 3).
- Urine sodium excretion increased for all 3 patients from an average of 147.7 mmol/L to an average of 377.6 mmol/L during the treatment period with a persistent increase in two of three patients in the 24-hour observation period after treatment with an average of 190.72 mmol/L (Figure2).
- Average creatinine at time of entry into the trial was 1.86 mg/dL and 1.82 mg/dL at the end of the treatment period and on average GFR increased during and after treatment (Figure 4).





Figure 3. Urine Output (mL)

Figure 4.



METHODS

- After successful animal studies, IRB approval was obtained at two institutions.
- Patients who presented with acute decompensated heart failure and diuretic resistance underwent placement of the rNPD device.
- Diuretic dose was maintained the same throughout the 72-hour urine measurement period to most accurately measure effect of rNPD. Prior to placement, urine output and response to diuretics was recorded during a 24-hour period of observation. The rNPD device was placed and negative pressure applied to the renal pelvis for 24 hours.
- Urine output, urine electrolytes, and cell counts were obtained from the rNPD device and urinary catheter.
- Continued measurements were made for an additional 24 hours following cessation of rNPD.

CONCLUSION

 Treatment of acute heart failure with rNPD represents a novel treatment for patients with acute decompensated heart failure and cardiorenal syndrome which may improve diuretic response by improving total urine output and natriuresis.



Narration by **Alex Parker**